| ABSTRACT Objective: To evaluate systematically the clinical effectiveness and safety of Shenqi Fuzheng injection (SFI) in the treatment of chronic heart failure (CHF). Methods:A literature search was conducted for retrieving randomized controlled trials (RCTs) on CHF treated by SFI in the Cochrane Library, PubMed, Embase, Sinomed, China National Knowledge Infrastructure Database, China Science and Technology Journal Database, Wanfang Database up to June 12nd, 2017. Two reviewers extracted information and assessed the quality of included RCTs by the Cochrane Risk of Bias Assessment Tool independently, and then data was analyzed with RevMan 5.3 software. Results:12 RCTs involving 1 061 participants were included. The result showed that SFI group could improve the clinical total effective rate about 22% (RR=1.22, 95%CI: 1.15 1.29, P< 0.000 01). In addition, SFI made left ventricular ejection fraction perfect (MD=7.98, 95%CI: 1.55 14.41, P<0.000 01), lowered left ventricular end diastolic diameter (MD=-4.66,95%CI: -5.99 -3.33, P<0.000 01), and increase stroke volume (MD=9.26, 95%CI: 6.62 11.90, P<0.000 01). There were 2 studies did not occure obvious adverse reactions, and 2 studies occurred 5 cases of adverse reactions. Conclusion:Compared with western medicine, SFI combined with conventional therapy is more effective in improving the clinical total effective rate, and perfecting cardiac indexes, but more RCTs with high quality needed to support our study further. Besides more researches needed to conduct as well to confirm its safety. |
